Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 2016. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing discloses that on January 14, 2016, various Directors and PDMRs acquired GSK Ordinary Shares through the reinvestment of dividends under the GSK ShareReward Plan. The acquisition price was 1368.87 pence per Share.
- Sir Andrew Witty: 43 Shares
- Mr R G Connor: 53 Shares
- Mr D S Redfern: 61 Shares
- Ms C Thomas: 61 Shares
- Mr P C Thomson: 31 Shares
- Dr P J T Vallance: 35 Shares
- Mrs V A Whyte: 42 Shares
- Other PDMRs: Acquired between 3 and 15 Shares each.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the specific share transactions listed above.
Investor Verification Points
- Verify the total number of shares acquired by insiders via the ShareReward Plan on January 14, 2016.
- Confirm the transaction price of 1368.87 pence per Share against market data for that date.
- Note that this filing contains no financial performance metrics or strategic updates.